Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

The best free games prove that you really don't need a dime to have a good time. With 2025 in full swing, your coffers might be looking sparse after the holiday season. But the good news is that ...

HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Arcturus Therapeutics in a research note on Monday, January 13th. Cantor Fitzgerald reiterated an ...

Arcturus is advancing its vaccine and rare disease pipeline with significant developments. The initiation of a BARDA-funded Phase 1 study for bird flu, along with ongoing studies in cystic ...